Infusionstherapie mit hochdosiertem 5-FU/Natriumfolinat in Kombination mit Mitomycin C (MMC): eine Dosiseskalations-Studie (Phase I) bei Patientinnen mit metastasiertem Mammakarzinom

Tauchert, S.; Maltaris, Theodoros; Ertan, Kubilay; Diedrich, K.; Schmidt, W.; Friedrich, M.

doi:10.1055/s-2005-917831

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination chemotherapies consisting of MMC and 5-FU have been shown to be effective in the palliative treatment of patients with advanced gastric or colorectal cancer [32][33][34][35]. In addition, MMC and 5-FU are active antineoplastic drugs that can be combined for the palliative therapy of MBC, even after intensive pretreatment [36][37][38]. More- formed in all patients who completed at least 1 cycle of therapy.…”

Section: Introductionmentioning

confidence: 99%

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer – a Retrospective Analysis

Eichbaum¹,

Gast²,

Brückner³

et al. 2008

Breast Care

View full text Add to dashboard Cite

Background: The aim of this study was to analyze the activity and tolerability of a combined chemotherapy with mitomycin C, folinic acid, and 5-fluorouracil (MiFoFU) in patients with hepatic metastases from breast cancer, and in particular in patients with impaired liver function. Pa-tients and Methods: We retrospectively studied the charts of 44 patients who were treated with a MiFoFU combination therapy because of progressive metastatic breast cancer. Predominant site of metastases was the liver. Primary endpoints were response and time to progression (TTP); secondary endpoints were overall survival (OS) and tolerability. Results: Median age prior to treatment was 59 years. A median of 6 treatment cycles were administered per patient. Clinical benefit rate amounted to 64%. A mean TTP of 9 months and a mean OS of 14 months were found. Main clinical signs of nonhematological toxicity were stomatitis, nausea, and diarrhea. Grade III/IV hematotoxicity was seen in only 9 patients. 16 patients showed clinical signs of liver dysfunction. A clinical benefit could be achieved in 8 of these patients. Conclusions: MiFoFU combination chemotherapy is a well-tolerated treatment alternative in the palliative therapy of patients with liver metastases from breast cancer. Particularly in patients with hepatic dysfunction, this regimen seems to represent a helpful treatment option.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer – a Retrospective Analysis

Eichbaum¹,

Gast²,

Brückner³

et al. 2008

Breast Care

View full text Add to dashboard Cite

show abstract

Infusionstherapie mit hochdosiertem 5-FU/Natriumfolinat in Kombination mit Mitomycin C (MMC): eine Dosiseskalations-Studie (Phase I) bei Patientinnen mit metastasiertem Mammakarzinom

Cited by 1 publication

References 0 publications

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer – a Retrospective Analysis

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer – a Retrospective Analysis

Contact Info

Product

Resources

About

Infusionstherapie mit hochdosiertem 5-FU/Natriumfolinat in Kombination mit Mitomycin C (MMC): eine Dosiseskalations-Studie (Phase I) bei Patientinnen mit metastasiertem Mammakarzinom

Cited by 1 publication

References 0 publications

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer &ndash; a Retrospective Analysis

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer &ndash; a Retrospective Analysis

Contact Info

Product

Resources

About

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer – a Retrospective Analysis

Combined Chemotherapy with Mitomycin C, Folinic Acid, and 5-Fluorouracil (MiFoFU) as Salvage Treatment for Patients with Liver Metastases from Breast Cancer – a Retrospective Analysis